Subotheni Thavaneswaran

Subotheni Thavaneswaran

Auto-generated profile, based on publicly available information

Subotheni Thavaneswaran

NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
MKMaya Kansara
Maya Kansara
FLFrank Lin
Frank Lin
DEDavid Espinoza
David Espinoza
JGJohn Grady
John Grady
DTDavid M. Thomas
David M. Thomas
Purpose: To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects. Patients and methods: In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods. Results: The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respectively. Rare cancers achieving an OTR included cholangiocarcinoma, perivascular epithelioid cell (PEComa), neuroendocrine, gallbladder and endometrial cancer. O + D was safe, with five serious adverse events related to the study drug(s) in 3 (6%) patients. A higher proportion of CD38 high B cells in the blood and higher CD40 expression in tumour was prognostic of survival. Conclusions: O + D demonstrated no new toxicity concerns and yielded a clinically meaningful PFS6 rate and durable OTRs across several cancers with HRR defects, including rare cancers.

12 October 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
MBMandy Ballinger
Mandy Ballinger
PBPhyllis Butow
Phyllis Butow
BMBettina Meiser
Bettina Meiser
DGDavid Goldstein
David Goldstein
MBMegan Best
Megan Best
Https://doi.org/10.18632/oncotarget.28076 Subotheni Thavaneswaran, Mandy Ballinger, Phyllis Butow, Bettina Meiser, David Goldstein, Frank Lin, Christine Napier, David Thomas, Megan Best

1 November 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
WCWei Yen Chan
Wei Yen Chan
RARay Asghari
Ray Asghari
JGJohn Grady
John Grady
MDMaegan Deegan
Maegan Deegan
DTDavid M. Thomas
David M. Thomas

9 September 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
FLFrank Lin
Frank Lin
JGJohn P. Grady
John P. Grady
DEDavid Espinoza
David Espinoza
MHMin Li Huang
Min Li Huang
DTDavid M. Thomas
David M. Thomas
This single-arm phase II non-randomised trial (ACTRN12619001265167) evaluated trastuzumab emtansine in solid cancers with HER2 amplification or mutation detected by comprehensive genomic profiling. The primary objective was objective response (OR), while secondary objectives included the time to progression (TTP) on study to TTP on prior therapy ratio, progression-free survival (PFS) and overall survival (OS). The cohort included 16 tumours with HER2 mutations (group 1) and 16 with HER2 amplification (group 2). After 17 months median follow-up, ORs occurred in 19% of group 1 (1 salivary gland carcinoma (SGC), 2 lung cancers) and 25% of group 2 (3 SGCs, 1 uterine carcinoma). Fourteen of 29 TTP-evaluable patients achieved a TTP ratio ≥1.3, including 10 without an OR. Median PFS and OS were 4.5 (95% CI 2.1–7.0) and 18.2 months (95% CI 8.1-not reached) respectively. Trastuzumab emtansine showed modest ORs and a favourable change in disease trajectory in select HER2-altered solid cancers.

17 August 2017 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
PKPeey Sei Kok
Peey Sei Kok
TPTimothy Price
Timothy Price
Introduction: Multimodality treatment of patients with locally advanced rectal cancer (LARC) has significantly improved local disease control, however the unaltered overall survival (OS) implicates an inability to further control micrometastases, providing rationale for intensified systemic treatment. A systematic review was conducted to evaluate the efficacy and toxicity of adding oxaliplatin to a fluoropyrimidine (intervention) compared with fluoropyrimidine alone (control) in the treatment of LARC. Methods: We searched CENTRAL, Medline Ovid, PubMed and EMBASE databases. Randomised trials comparing the intervention and control delivered either pre- or post-operatively were included. Results: Seven trials involving 4444 patients were identified; five studies evaluated the intervention vs control preoperatively; one study peri-operatively; and one, post-operatively. There was no significant difference in OS with oxaliplatin addition, HR 0.89, 95% CI, 0.75 to 1.06. There was however an improvement in disease free survival, 3-year local and distant recurrence rates (RR) favouring oxaliplatin. Preoperative oxaliplatin improved pathological complete response (pCR), but with a greater toxicity and reduced compliance with radiation. Conclusion: There is no OS benefit with oxaliplatin, despite improved pCR, local and distant RR. Before drawing definitive conclusions, longer follow-up in included trials and availability of published data from other eligible studies, including the induction setting, are needed.

18 October 2024 in Surgery
Verified
Journal Article
Closed access
ENElan Novis
Elan Novis
AGAnthony Glover
Anthony Glover
JGJohn Grady
John Grady
ASAudrey Silvestri
Audrey Silvestri
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
DTDavid M. Thomas
David M. Thomas